Literature DB >> 28844517

Coronary Computed Tomographic Angiography-Derived Fractional Flow Reserve Based on Machine Learning for Risk Stratification of Non-Culprit Coronary Narrowings in Patients with Acute Coronary Syndrome.

Taylor M Duguay1, Christian Tesche2, Rozemarijn Vliegenthart3, Carlo N De Cecco1, Han Lin1, Moritz H Albrecht4, Akos Varga-Szemes1, Domenico De Santis5, Ullrich Ebersberger6, Richard R Bayer7, Sheldon E Litwin7, Ellen Hoffmann6, Daniel H Steinberg7, U Joseph Schoepf8.   

Abstract

This study investigated the prognostic value of coronary computed tomography angiography (cCTA)-derived fractional flow reserve (CT-FFR) in patients with acute coronary syndrome (ACS) and multivessel disease to gauge significance and guide management of non-culprit lesions. We retrospectively analyzed data of 48 patients (56 ± 10 years, 60% men) who were admitted for symptoms suggestive of ACS and underwent dual-source cCTA followed by invasive coronary angiography with culprit lesion intervention. Culprit lesions were retrospectively identified on cCTA using images obtained during invasive coronary angiography. Non-culprit lesions with ≥25% luminal stenosis and deferred intervention were evaluated using a machine learning CT-FFR algorithm to determine lesion-specific ischemia (CT-FFR ≤0.80). Follow-up was performed. CT-FFR identified lesion-specific ischemia in 23 of 81 non-culprit lesions. After a median follow-up of 19.5 months, 14 patients (29%) had major adverse cardiac events (MACE). Univariate Cox regression analysis revealed that CT-FFR ≤0.80 (hazard ratio [HR] 3.77 [95% confidence interval 1.16 to 12.29], p = 0.027), Framingham risk score (FRS) (HR 2.96 [1.01 to 7.63], p = 0.038), and a CAD-RADS classification ≥3 (HR 3.12 [1.03 to 10.17], p = 0.051) were predictors of MACE. In a risk-adjusted model controlling for FRS and CAD-RADS ≥3, CT-FFR ≤0.80 remained a predictor of MACE (1.56 [1.01 to 2.83], p = 0.048). Receiver operating characteristics analysis including FRS, CAD-RADS ≥ 3, and CT-FFR ≤0.80 (area under the curve 0.78) showed incremental discriminatory power over FRS alone (area under the curve 0.66, p = 0.032). CT-FFR of non-culprit lesions in patients with ACS and multivessel disease adds prognostic value to identify risk of future MACE.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28844517     DOI: 10.1016/j.amjcard.2017.07.008

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Non-invasive fractional flow reserve derived from coronary computed tomography angiography in patients with acute chest pain: Subgroup analysis of the ROMICAT II trial.

Authors:  Maros Ferencik; Michael T Lu; Thomas Mayrhofer; Stefan B Puchner; Ting Liu; Pal Maurovich-Horvat; Khristine Ghemigian; Alexander Ivanov; Elizabeth Adami; John T Nagurney; Pamela K Woodard; Quynh A Truong; James E Udelson; Udo Hoffmann
Journal:  J Cardiovasc Comput Tomogr       Date:  2019-05-15

Review 2.  Machine Learning and Deep Neural Networks in Thoracic and Cardiovascular Imaging.

Authors:  Tara A Retson; Alexandra H Besser; Sean Sall; Daniel Golden; Albert Hsiao
Journal:  J Thorac Imaging       Date:  2019-05       Impact factor: 3.000

3.  Inter- and Intraoperator Variability in Measurement of On-Site CT-derived Fractional Flow Reserve Based on Structural and Fluid Analysis: A Comprehensive Analysis.

Authors:  Kanako K Kumamaru; Erin Angel; Kelsey N Sommer; Vijay Iyer; Michael F Wilson; Nikhil Agrawal; Aishwarya Bhardwaj; Sharma B Kattel; Sandra Kondziela; Saurabh Malhotra; Christopher Manion; Katherine Pogorzelski; Tharmathai Ramanan; Abhishek C Sawant; Mary M Suplicki; Sameer Waheed; Shinichiro Fujimoto; Umesh C Sharma; Frank J Rybicki; Ciprian N Ionita
Journal:  Radiol Cardiothorac Imaging       Date:  2019-08-29

4.  Prognostic value of CT-derived myocardial blood flow, CT fractional flow reserve and high-risk plaque features for predicting major adverse cardiac events.

Authors:  Lihua Yu; Zhigang Lu; Xu Dai; Chengxing Shen; Lei Zhang; Jiayin Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2021-08

5.  Fractional flow reserve derived from CCTA may have a prognostic role in myocardial bridging.

Authors:  Fan Zhou; Chun Xiang Tang; U Joseph Schoepf; Christian Tesche; Maximilian J Bauer; Brian E Jacobs; Chang Sheng Zhou; Jing Yan; Meng Jie Lu; Guang Ming Lu; Long Jiang Zhang
Journal:  Eur Radiol       Date:  2018-10-30       Impact factor: 5.315

6.  The correlation of deep learning-based CAD-RADS evaluated by coronary computed tomography angiography with breast arterial calcification on mammography.

Authors:  Zengfa Huang; Jianwei Xiao; Yuanliang Xie; Yun Hu; Shutong Zhang; Xiang Li; Zheng Wang; Zuoqin Li; Xiang Wang
Journal:  Sci Rep       Date:  2020-07-13       Impact factor: 4.379

Review 7.  Machine Learning for Assessment of Coronary Artery Disease in Cardiac CT: A Survey.

Authors:  Nils Hampe; Jelmer M Wolterink; Sanne G M van Velzen; Tim Leiner; Ivana Išgum
Journal:  Front Cardiovasc Med       Date:  2019-11-26

8.  Coronary Computed Tomography Angiography-Derived Fractional Flow Reserve in Patients with Anomalous Origin of the Right Coronary Artery from the Left Coronary Sinus.

Authors:  Chun Xiang Tang; Meng Jie Lu; Joseph Uwe Schoepf; Christian Tesche; Maximilian Bauer; John Nance; Parkwood Griffith; Guang Ming Lu; Long Jiang Zhang
Journal:  Korean J Radiol       Date:  2020-02       Impact factor: 3.500

Review 9.  Artificial Intelligence Advancements in the Cardiovascular Imaging of Coronary Atherosclerosis.

Authors:  Pedro Covas; Eison De Guzman; Ian Barrows; Andrew J Bradley; Brian G Choi; Joseph M Krepp; Jannet F Lewis; Richard Katz; Cynthia M Tracy; Robert K Zeman; James P Earls; Andrew D Choi
Journal:  Front Cardiovasc Med       Date:  2022-03-21

Review 10.  Artificial Intelligence-A Good Assistant to Multi-Modality Imaging in Managing Acute Coronary Syndrome.

Authors:  Ming-Hao Liu; Chen Zhao; Shengfang Wang; Haibo Jia; Bo Yu
Journal:  Front Cardiovasc Med       Date:  2022-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.